Publication | Closed Access
Assessment of the response in vivo and in vitro of Plasmodium falciparum to sulphadoxine-pyrimethamine in the malarious areas of Iran.
31
Citations
0
References
1993
Year
Disease ResistanceHealth SciencesMalarious AreasAntiparasitic AgentMedicineMalariaParasite ControlPlasmodium Falciparum CasesToxicologyPlasmodium FalciparumPharmacologySe IranClinical MicrobiologyParasitologyDrug Resistance
Studies of drug resistance of Plasmodium falciparum cases from SE Iran were carried out in vivo and in vitro during 1990-91. In a study of 26 chloroquine-resistant infections, using amodiaquine (25 mg kg-1 over 3 days), followed by two-thirds of the standard dose of sulphadoxine-pyrimethamine, six cases were resistant at the RI(3) and RII(3) levels. An additional study testing the standard dose of sulphadoxine-pyrimethamine in 43 chloroquine-resistant cases revealed five (11.6%) resistant at the RI(2) and RII(3) levels. Six of the above resistant infections were contracted in Hormozgan, three in Sistan-Baluchestan, one in Kerman provinces of Iran and one in Pakistan. In five of 22 successful in-vitro tests, carried out on different isolates, the parasites grew to schizonts (> or = 8 nuclei) in the wells containing 1000 pmol sulphadoxine and 12.5 pmol pyrimethamine, indicative of resistance.